,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,608,1,6,,11537593,5280489,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
1,875,1,2,,26750098,5280489,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
2,880,2,1,,26750098,5280489,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
3,880,2,1,,26750098,5280489,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
4,881,2,2,,26750098,5280489,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
5,884,1,2,,26750098,5280489,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
6,885,1,2,,26750098,5280489,Unspecified,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
7,887,1,2,,26750098,5280489,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
8,889,1,3,,26750098,5280489,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
9,892,1,2,,26750098,5280489,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
10,893,1,2,,26750098,5280489,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
11,893,1,2,,26750098,5280489,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
12,894,2,1,,26750098,5280489,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
13,900,1,3,,26750098,5280489,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
14,902,1,2,,26750098,5280489,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
15,910,1,2,,26750098,5280489,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
16,923,1,2,,26750098,5280489,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
17,924,1,2,,26750098,5280489,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
18,927,1,3,,26750098,5280489,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
19,930,1,2,,26750098,5280489,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
20,995,1,2,,26750098,5280489,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
21,1030,2,1,,26750098,5280489,Inconclusive,30582681.0,216.0,35.4813,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
22,1033,2,2,,11537593,5280489,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
23,1189,1,5,,48413385,5280489,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
24,1194,1,3,,48413385,5280489,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
25,1195,1,2,,48415624,5280489,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
26,1199,1,3,,48413385,5280489,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
27,1205,1,4,,48413385,5280489,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
28,1208,1,3,,48413385,5280489,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
29,1376,1,2,,47193664,5280489,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
30,1379,1,2,,26750098,5280489,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
31,1385,2,2,,47193664,5280489,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
32,1422,1,1,,47193664,5280489,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
33,1452,1,1,,26750098,5280489,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
34,1454,1,1,,26750098,5280489,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
35,1457,1,1,,26750098,5280489,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
36,1458,1,1,,26750098,5280489,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
37,1460,1,3,,26750098,5280489,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
38,1463,1,1,,26750098,5280489,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
39,1465,1,1,,47193664,5280489,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
40,1467,1,3,,26750098,5280489,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
41,1468,1,1,,26750098,5280489,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
42,1469,1,1,,26750098,5280489,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
43,1471,2,1,,26750098,5280489,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
44,1476,2,1,,26750098,5280489,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
45,1478,2,1,,26750098,5280489,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
46,1479,1,2,,26750098,5280489,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
47,1487,1,1,,26750098,5280489,Inconclusive,27436948.0,4000.0,35.4813,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
48,1490,2,1,,26750098,5280489,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
49,1511,1,3,,47193664,5280489,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
50,1519,1,3,,26750098,5280489,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
51,1529,1,1,,47193664,5280489,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
52,1530,1,1,,47193664,5280489,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
53,1531,1,1,,47193664,5280489,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
54,1532,1,1,,47193664,5280489,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
55,1549,1,2,,11537593,5280489,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
56,1552,1,3,,11537593,5280489,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
57,1554,1,1,,47193664,5280489,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
58,1580,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
59,1581,1,1,,8149219,5280489,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
60,1582,1,1,,8149219,5280489,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
61,1583,1,1,,8149219,5280489,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
62,1584,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
63,1585,1,1,,8149219,5280489,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
64,1586,1,1,,8149219,5280489,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
65,1587,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
66,1588,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
67,1589,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
68,1590,1,1,,8149219,5280489,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
69,1593,1,1,,8149219,5280489,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
70,1594,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
71,1595,1,1,,8149219,5280489,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
72,1596,1,1,,8149219,5280489,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
73,1597,1,1,,8149219,5280489,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
74,1598,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
75,1599,1,1,,8149219,5280489,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
76,1600,1,1,,8149219,5280489,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
77,1601,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
78,1602,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
79,1603,1,1,,8149219,5280489,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
80,1604,1,1,,8149219,5280489,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
81,1605,1,1,,8149219,5280489,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
82,1606,1,1,,8149219,5280489,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
83,1607,1,1,,8149219,5280489,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
84,1608,1,1,,8149219,5280489,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
85,1609,1,1,,8149219,5280489,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
86,1610,1,1,,8149219,5280489,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
87,1612,1,1,,8149219,5280489,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
88,1613,1,1,,8149219,5280489,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
89,1614,1,1,,8149219,5280489,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
90,1616,1,1,,8149219,5280489,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
91,1621,1,2,,47193664,5280489,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
92,1626,1,2,,47193664,5280489,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
93,1637,1,2,,11537593,5280489,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
94,1648,1,2,,11537593,5280489,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
95,1662,1,2,,47193664,5280489,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
96,1663,1,2,,47193664,5280489,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
97,1672,1,3,,47193664,5280489,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
98,1688,1,1,,26750098,5280489,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
99,1766,1,1,,26750098,5280489,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
100,1766,1,1,,26750098,5280489,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
101,1768,1,1,,26750098,5280489,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
102,1768,1,1,,26750098,5280489,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
103,1813,1,2,,47193664,5280489,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
104,1814,1,2,,47193664,5280489,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
105,1832,2,1,,47193664,5280489,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
106,1850,2,1,,47193664,5280489,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
107,1863,2,1,,47193664,5280489,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
108,1865,1,1,,26750098,5280489,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
109,1875,2,1,,47193664,5280489,Inconclusive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
110,1885,2,1,,47193664,5280489,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
111,1899,1,3,,47193664,5280489,Active,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
112,1903,2,3,,47193664,5280489,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
113,1906,1,3,,47193664,5280489,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
114,1910,1,2,,47193664,5280489,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
115,1947,1,2,,47193664,5280489,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
116,1948,1,1,,26750098,5280489,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
117,1950,1,3,,47193664,5280489,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
118,1956,1,1,,47193664,5280489,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
119,1962,1,2,,47193664,5280489,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
120,1974,1,2,,47193664,5280489,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
121,1979,1,1,,47193664,5280489,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
122,1987,1,2,,47193664,5280489,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
123,2016,1,3,,47193664,5280489,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
124,2023,1,3,,47193664,5280489,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
125,2025,1,3,,47193664,5280489,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
126,2029,1,3,,47193664,5280489,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
127,2052,2,1,,47193664,5280489,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
128,2057,1,2,,47193664,5280489,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
129,2066,1,4,,47193664,5280489,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
130,2094,1,2,,47193664,5280489,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
131,2094,1,2,,47193664,5280489,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
132,2094,1,2,,47193664,5280489,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
133,2097,1,2,,47193664,5280489,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
134,2098,1,1,,47193664,5280489,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
135,2099,1,1,,47193664,5280489,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
136,2101,1,1,,26750098,5280489,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
137,2107,1,1,,26750098,5280489,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
138,2112,1,1,,26750098,5280489,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
139,2129,1,2,,47193664,5280489,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
140,2130,1,3,,47193664,5280489,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
141,2147,1,1,,26750098,5280489,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
142,2152,1,2,,47193664,5280489,Inactive,83779224.0,,,,TR-FRET-based biochemical high-throughput confirmation assay for inhibitors of Hepatitis C Virus (HCV) core protein dimerization.,Screening,,
143,2156,2,2,,47193664,5280489,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
144,2159,1,3,,47193664,5280489,Inactive,83779224.0,,29.693,IC50,TR-FRET-based biochemical high-throughput dose response assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization.,Confirmatory,,
145,2174,1,3,,47193664,5280489,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
146,2177,1,3,,47193664,5280489,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
147,2216,1,3,,47193664,5280489,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
148,2221,1,2,,47193664,5280489,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
149,2227,1,2,,47193664,5280489,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
150,2234,1,2,,47193664,5280489,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
151,2235,1,2,,47193664,5280489,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
152,2237,1,2,,47193664,5280489,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
153,2239,1,2,,47193664,5280489,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
154,2247,1,2,,47193664,5280489,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
155,2280,2,3,,47193664,5280489,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
156,2300,1,3,,47193664,5280489,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
157,2380,1,2,,47193664,5280489,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
158,2391,1,1,,47193664,5280489,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
159,2435,1,2,,47193664,5280489,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
160,2445,1,2,,47193664,5280489,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
161,2451,1,2,,26750098,5280489,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
162,2462,1,1,,47193664,5280489,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
163,2462,1,1,,47193664,5280489,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
164,2472,1,2,,26750098,5280489,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
165,2488,1,1,,87219208,5280489,Inactive,83779224.0,,49.751000000000005,IC50,Late stage results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: TR-FRET-based biochemical dose response assay for HCV core inhibitors,Confirmatory,,
166,2517,2,1,,144205110,5280489,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
167,2520,1,4,,47193664,5280489,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
168,2521,1,3,,47193664,5280489,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
169,2524,1,2,,47193664,5280489,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
170,2528,1,2,,26750098,5280489,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
171,2540,1,2,,47193664,5280489,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
172,2544,1,2,,47193664,5280489,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
173,2546,1,1,,26750098,5280489,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
174,2549,1,1,,26750098,5280489,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
175,2550,1,3,,47193664,5280489,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
176,2551,1,1,,26750098,5280489,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
177,2553,1,2,,47193664,5280489,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
178,2557,1,3,,47193664,5280489,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
179,2563,1,1,,47193664,5280489,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
180,2599,1,2,,47193664,5280489,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
181,2606,1,2,,47193664,5280489,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
182,2629,1,1,,47193664,5280489,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
183,2642,1,2,,47193664,5280489,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
184,2648,1,2,,47193664,5280489,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
185,2650,2,1,,47193664,5280489,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
186,2661,1,1,,47193664,5280489,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
187,2662,2,1,,26750098,5280489,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
188,2690,1,2,,47193664,5280489,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
189,2716,1,1,,47193664,5280489,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
190,2717,1,2,,47193664,5280489,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
191,2718,1,1,,47193664,5280489,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
192,2751,2,2,,47193664,5280489,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
193,2796,1,4,,47193664,5280489,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
194,2797,1,2,,47193664,5280489,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
195,2805,2,2,,47193664,5280489,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
196,2806,2,2,,47193664,5280489,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
197,2825,1,2,,47193664,5280489,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
198,41895,3,7,,103401011,5280489,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
199,211861,6,3,,103401011,5280489,Unspecified,,,,,Compound was tested for its toxicity after oral administration in mice,Other,,
200,212004,6,3,,103401011,5280489,Unspecified,,,,,The activity was measured in mice after oral administration of the compound,Other,,
201,287070,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 1000 mol ratio/32 pmol TPA relative to TPA,Other,17477572.0,
202,287071,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 500 mol ratio/32 pmol TPA relative to TPA,Other,17477572.0,
203,287072,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 100 mol ratio/32 pmol TPA relative to TPA,Other,17477572.0,
204,287073,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 10 mol ratio/32 pmol TPA relative to TPA,Other,17477572.0,
205,287074,3,4,,103401011,5280489,Unspecified,,,,,Cell viability of Raji cells at 1000 mol ratio/32 pmol TPA,Other,17477572.0,
206,287077,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr Virus early antigen activation in Raji cells at 1000 mol ratio/32 pmol TPA relative to TPA,Other,17480098.0,
207,287078,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr Virus early antigen activation in Raji cells at 500 mol ratio/32 pmol TPA relative to TPA,Other,17480098.0,
208,287079,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr Virus early antigen activation in Raji cells at 100 mol ratio/32 pmol TPA relative to TPA,Other,17480098.0,
209,287080,3,4,,103401011,5280489,Unspecified,,,,,Inhibitory effect on TPA-induced Epstein-Barr Virus early antigen activation in Raji cells at 10 mol ratio/32 pmol TPA relative to TPA,Other,17480098.0,
210,287081,3,4,,103401011,5280489,Unspecified,,,,,Cell viability of Raji cells at 1000 mol ratio/32 pmol TPA relative to TPA,Other,17480098.0,
211,288566,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 1000 mol ratio/32 pmol TPA relative to control,Other,17488130.0,
212,288567,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 500 mol ratio/32 pmol TPA relative to control,Other,17488130.0,
213,288568,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 100 mol ratio/32 pmol TPA relative to control,Other,17488130.0,
214,288569,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 10 mol ratio/32 pmol TPA relative to control,Other,17488130.0,
215,288570,3,4,,103401011,5280489,Unspecified,,,,,Cell viability of Raji cells,Other,17488130.0,
216,288760,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 320 nM after 48 hrs relative to TPA,Other,17503850.0,
217,288761,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 32 nM after 48 hrs relative to TPA,Other,17503850.0,
218,288762,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 3.2 nM after 48 hrs relative to TPA,Other,17503850.0,
219,288763,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 0.32 nM after 48 hrs relative to TPA,Other,17503850.0,
220,288764,4,4,,103401011,5280489,Active,,,0.0127,IC50,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs,Confirmatory,17503850.0,
221,288765,3,4,,103401011,5280489,Unspecified,,,,,Cell viability of Raji cells at 320 nM,Other,17503850.0,
222,311267,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen in Raji cells at 1000 mol ratio/TPA relative to control,Other,17685651.0,
223,311268,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen in Raji cells at 500 mol ratio/TPA relative to control,Other,17685651.0,
224,311269,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen in Raji cells at 100 mol ratio/TPA relative to control,Other,17685651.0,
225,311270,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen in Raji cells at 10 mol ratio/TPA relative to control,Other,17685651.0,
226,311272,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 mol ratio/TPA relative to control,Other,17685651.0,
227,323922,6,2,,103401011,5280489,Active,,,6.3,EC50,Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay,Confirmatory,17420205.0,
228,323923,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human OR6 cells after 120 hrs by cell viability assay,Other,17420205.0,
229,323924,3,3,,103401011,5280489,Active,,,,,Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/C-5B/KE/poly cells after 72 hrs by luciferase reporter assay,Other,17420205.0,
230,323925,3,3,,103401011,5280489,Active,,,,,Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/3-5B/KE/poly cells after 72 hrs by luciferase reporter assay,Other,17420205.0,
231,323928,3,3,,103401011,5280489,Active,,,,,Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 24 hrs by luciferase reporter assay,Other,17420205.0,
232,323929,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human OR6 cells after 72 hrs,Other,17420205.0,
233,323932,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human OR6 cells after 120 hrs,Other,17420205.0,
234,332212,3,5,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs relative to TPA,Other,11858748.0,
235,332213,3,5,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs relative to TPA,Other,11858748.0,
236,332214,3,5,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs relative to TPA,Other,11858748.0,
237,332215,3,5,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs relative to TPA,Other,11858748.0,
238,332216,3,5,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue assay,Other,11858748.0,
239,332228,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs relative to TPA,Other,11858752.0,
240,332229,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs relative to TPA,Other,11858752.0,
241,332230,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs relative to TPA,Other,11858752.0,
242,332231,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs relative to TPA,Other,11858752.0,
243,332232,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue assay,Other,11858752.0,
244,333230,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 32 nM after 48 hrs relative to control,Other,15387647.0,
245,333231,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells at 32 nM after 48 hrs by trypan blue staining method,Other,15387647.0,
246,333232,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 16 nM after 48 hrs relative to control,Other,15387647.0,
247,333233,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells at 16 nM after 48 hrs by trypan blue staining method,Other,15387647.0,
248,333234,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 3.2 nM after 48 hrs relative to control,Other,15387647.0,
249,333235,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells at 3.2 nM after 48 hrs by trypan blue staining method,Other,15387647.0,
250,333236,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 0.32 nM after 48 hrs relative to control,Other,15387647.0,
251,333237,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells at 0.32 nM after 48 hrs by trypan blue staining method,Other,15387647.0,
252,336754,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 32 nmol after 48 hrs relative to control,Other,12662094.0,
253,336755,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 16 nmol after 48 hrs relative to control,Other,12662094.0,
254,336756,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 3.2 nmol after 48 hrs relative to control,Other,12662094.0,
255,336757,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 0.32 nmol after 48 hrs relative to control,Other,12662094.0,
256,336758,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation after 48 hrs relative to control,Other,12662094.0,
257,336759,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 32 nmol after 48 hrs by trypan blue staining,Other,12662094.0,
258,336760,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 16 nmol after 48 hrs by trypan blue staining,Other,12662094.0,
259,336761,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 3.2 nmol after 48 hrs by trypan blue staining,Other,12662094.0,
260,336762,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue staining,Other,12662094.0,
261,338907,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA,Other,11975480.0,
262,338908,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA,Other,11975480.0,
263,338909,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA,Other,11975480.0,
264,338910,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA,Other,11975480.0,
265,338911,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio,Other,11975480.0,
266,354407,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 32 nmol after 48 hrs relative to TPA,Other,12608849.0,
267,354408,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 16 nmol after 48 hrs relative to TPA,Other,12608849.0,
268,354409,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 3.2 nmol after 48 hrs relative to TPA,Other,12608849.0,
269,354410,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 0.32 nmol after 48 hrs relative to TPA,Other,12608849.0,
270,354411,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells per 32 pmol TPA after 48 hrs,Other,12608849.0,
271,354412,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 32 nmol after 48 hrs by trypan blue assay,Other,12608849.0,
272,354413,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 16 nmol after 48 hrs by trypan blue assay,Other,12608849.0,
273,354414,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 3.2 nmol after 48 hrs by trypan blue assay,Other,12608849.0,
274,354415,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue assay,Other,12608849.0,
275,355396,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 0.32 nmol after 48 hrs by trypan blue staining method,Other,14695799.0,
276,355401,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio by trypan blue staining method,Other,14695801.0,
277,355402,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 1000 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique,Other,14695801.0,
278,355403,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 500 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique,Other,14695801.0,
279,355404,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 100 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique,Other,14695801.0,
280,355405,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 10 molar ratio relative to 12-O-tetradecanoylphorbol-13-acetate by immunofluorescence technique,Other,14695801.0,
281,355406,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed per 32 pmol TPA by immunofluorescence technique,Other,14695801.0,
282,356191,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs relative to TPA,Other,12932121.0,
283,356192,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs relative to TPA,Other,12932121.0,
284,356193,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs relative to TPA,Other,12932121.0,
285,356194,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs relative to TPA,Other,12932121.0,
286,356195,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio/TPA after 48 hrs,Other,12932121.0,
287,356196,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio/TPA after 48 hrs,Other,12932121.0,
288,356197,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio/TPA after 48 hrs,Other,12932121.0,
289,356198,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio/TPA after 48 hrs,Other,12932121.0,
290,356611,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as early antigen induction at 1000 molar ratio after 48 hrs by conventional indirect immunofluorescence technique relative to TPA,Other,14640522.0,
291,356612,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as early antigen induction at 500 molar ratio after 48 hrs by conventional indirect immunofluorescence technique relative to TPA,Other,14640522.0,
292,356613,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as early antigen induction at 100 molar ratio after 48 hrs by conventional indirect immunofluorescence technique relative to TPA,Other,14640522.0,
293,356614,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as early antigen induction at 10 molar ratio after 48 hrs by conventional indirect immunofluorescence technique relative to TPA,Other,14640522.0,
294,356615,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue staining method,Other,14640522.0,
295,356680,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 32 nmol relative to 12-O-tetradecanoylphorbol-13-acetate,Other,14695799.0,
296,356681,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 16 nmol relative to 12-O-tetradecanoylphorbol-13-acetate,Other,14695799.0,
297,356682,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 3.2 nmol relative to 12-O-tetradecanoylphorbol-13-acetate,Other,14695799.0,
298,356683,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 0.32 nmol relative to 12-O-tetradecanoylphorbol-13-acetate,Other,14695799.0,
299,356684,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed per 32 pmol TPA,Other,14695799.0,
300,356685,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 32 nmol after 48 hrs by trypan blue staining method,Other,14695799.0,
301,356686,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 16 nmol after 48 hrs by trypan blue staining method,Other,14695799.0,
302,356687,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 3.2 nmol after 48 hrs by trypan blue staining method,Other,14695799.0,
303,361190,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs relative to TPA,Other,11429990.0,
304,361191,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs relative to TPA,Other,11429990.0,
305,361192,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs relative to TPA,Other,11429990.0,
306,361193,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs relative to TPA,Other,11429990.0,
307,361194,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation per 32 pmol TPA after 48 hrs,Other,11429990.0,
308,361195,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue staining relative to TPA,Other,11429990.0,
309,361196,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio after 48 hrs by trypan blue staining relative to TPA,Other,11429990.0,
310,361197,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio after 48 hrs by trypan blue staining relative to TPA,Other,11429990.0,
311,361198,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio after 48 hrs by trypan blue staining relative to TPA,Other,11429990.0,
312,378043,3,3,,103401011,5280489,Unspecified,,,,,Antiradical activity assessed as DPPH radical scavenging activity at 1500 uM by spectrophotometry relative to control,Other,16933864.0,
313,378050,3,3,,103401011,5280489,Active,,,,,Antiradical activity assessed as DPPH radical scavenging activity at 1050 uM by spectrophotometry relative to control,Other,16933864.0,
314,379565,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA,Other,17190444.0,
315,379566,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA,Other,17190444.0,
316,379567,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA,Other,17190444.0,
317,379568,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA,Other,17190444.0,
318,379569,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA,Other,17190444.0,
319,379570,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio,Other,17190444.0,
320,379571,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio,Other,17190444.0,
321,379572,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio,Other,17190444.0,
322,379573,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio,Other,17190444.0,
323,381367,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 1000 mol ratio relative to TPA,Other,10869208.0,
324,381368,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 500 mol ratio relative to TPA,Other,10869208.0,
325,381369,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 100 mol ratio relative to TPA,Other,10869208.0,
326,381370,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 10 mol ratio relative to TPA,Other,10869208.0,
327,381371,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio/TPA,Other,10869208.0,
328,398024,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 1000 mol ratio relative to TPA,Other,12502340.0,
329,398025,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 500 mol ratio relative to TPA,Other,12502340.0,
330,398026,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 100 mol ratio relative to TPA,Other,12502340.0,
331,398027,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 10 mol ratio relative to TPA,Other,12502340.0,
332,398028,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hours relative to TPA,Other,12502340.0,
333,400253,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs relative to TPA,Other,15043419.0,
334,400254,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs relative to TPA,Other,15043419.0,
335,400255,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs relative to TPA,Other,15043419.0,
336,400256,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs relative to TPA,Other,15043419.0,
337,400257,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio by trypan blue assay,Other,15043419.0,
338,400339,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 1000 molar ratio relative to TPA,Other,8984150.0,
339,400340,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 500 molar ratio relative to TPA,Other,8984150.0,
340,400341,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 100 molar ratio relative to TPA,Other,8984150.0,
341,400342,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 10 molar ratio relative to TPA,Other,8984150.0,
342,400343,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio,Other,8984150.0,
343,400344,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio,Other,8984150.0,
344,400345,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio,Other,8984150.0,
345,400346,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio,Other,8984150.0,
346,400777,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 1000 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control,Other,9599262.0,
347,400778,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 500 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control,Other,9599262.0,
348,400779,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 100 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control,Other,9599262.0,
349,400780,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 10 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control,Other,9599262.0,
350,400781,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs,Other,9599262.0,
351,403810,3,3,,103401011,5280489,Unspecified,,,,,"Octanol-water partition coefficient, log POW of the compound",Other,16180819.0,
352,434955,1,2,,47193664,5280489,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
353,434962,1,2,,47193664,5280489,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
354,434973,1,3,,47193664,5280489,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
355,434989,1,1,,47193664,5280489,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
356,435003,1,3,,47193664,5280489,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
357,435005,1,1,,47193664,5280489,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
358,435022,2,2,,47193664,5280489,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
359,435030,1,2,,47193664,5280489,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
360,435030,1,2,,47193664,5280489,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
361,449728,1,2,,47193664,5280489,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
362,449739,1,2,,47193664,5280489,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
363,449762,1,2,,47193664,5280489,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
364,449763,1,3,,47193664,5280489,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
365,449768,1,1,,47193664,5280489,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
366,452853,5,2,,103401011,5280489,Active,,,16.9,IC50,Antioxidant activity assessed as hydrogen peroxide scavenging activity by peroxyoxalate chemiluminescent method,Confirmatory,19853459.0,
367,463079,1,2,,47193664,5280489,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
368,463082,1,1,,47193664,5280489,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
369,463085,2,2,,87219208,5280489,Inactive,83779224.0,,34.8,IC50,Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Luminescence-based biochemical AlphaScreen assay to identify inhibitors of HCV core dimerization,Confirmatory,,
370,463104,1,2,,47193664,5280489,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
371,463111,1,1,,47193664,5280489,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
372,463141,1,2,,47193664,5280489,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
373,463165,1,1,,47193664,5280489,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
374,463190,1,2,,47193664,5280489,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
375,463195,1,2,,47193664,5280489,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
376,463210,1,2,,47193664,5280489,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
377,463212,1,1,,47193664,5280489,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
378,463751,3,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation at 32 uM,Other,20102168.0,
379,463752,3,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation at 16 uM,Other,20102168.0,
380,463753,3,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation at 3.2 uM,Other,20102168.0,
381,463754,3,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation at 0.32 uM,Other,20102168.0,
382,466187,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs relative to TPA by indirect immunofluorescence technique,Other,20146433.0,
383,466188,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 500 molar ratio after 48 hrs relative to TPA by indirect immunofluorescence technique,Other,20146433.0,
384,466189,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 100 molar ratio after 48 hrs relative to TPA by indirect immunofluorescence technique,Other,20146433.0,
385,466190,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 10 molar ratio after 48 hrs relative to TPA by indirect immunofluorescence technique,Other,20146433.0,
386,466191,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells carrying EBV genome by trypan blue staining method,Other,20146433.0,
387,472356,3,4,,103401011,5280489,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio,Other,19746919.0,
388,472358,4,3,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells relative to TPA,Other,19746919.0,
389,472359,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 10 molar relative to TPA,Other,19746919.0,
390,472360,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 100 molar relative to TPA,Other,19746919.0,
391,472361,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 1000 molar relative to TPA,Other,19746919.0,
392,472362,3,4,,103401011,5280489,Unspecified,,,,,Inhibition of TPA-induced EBV early antigen activation in human Raji cells at 500 molar relative to TPA,Other,19746919.0,
393,485270,1,1,,47193664,5280489,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
394,485272,1,1,,47193664,5280489,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
395,485273,2,1,,47193664,5280489,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
396,485275,1,3,,47193664,5280489,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
397,485280,2,1,,87219208,5280489,Inactive,,,24.7,CC50,Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Absorbance-based cell-based assay to identify compounds that are cytotoxic to Huh-7.5 cells,Confirmatory,,
398,485281,1,1,,26750098,5280489,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
399,485290,1,1,,26750098,5280489,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
400,485317,1,2,,47193664,5280489,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
401,485346,1,1,,47193664,5280489,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
402,485346,1,1,,47193664,5280489,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
403,488847,1,3,,47193664,5280489,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
404,488890,1,2,,47193664,5280489,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
405,488922,1,2,,47193664,5280489,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
406,488975,1,2,,47193664,5280489,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
407,488977,1,2,,47193664,5280489,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
408,489030,2,1,,47193664,5280489,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
409,489031,2,1,,47193664,5280489,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
410,492140,3,3,,103401011,5280489,Unspecified,,,,,Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay,Other,20565070.0,
411,492961,1,1,,26750098,5280489,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
412,492967,1,2,,99301418,5280489,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
413,493011,1,1,,47193664,5280489,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
414,493012,1,1,,47193664,5280489,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
415,493036,1,2,,47193664,5280489,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
416,493162,1,2,,99301418,5280489,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
417,504327,1,1,,26750098,5280489,Inconclusive,153791535.0,2648.0,31.6228,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
418,504332,1,1,,26750098,5280489,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
419,504406,1,1,,47193664,5280489,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
420,504408,2,1,,47193664,5280489,Active,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
421,504749,1,3,,26750098,5280489,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
422,504749,1,3,1.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
423,504749,1,3,2.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
424,504749,1,3,3.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
425,504749,1,3,4.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
426,504749,1,3,5.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
427,504749,1,3,6.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
428,504749,1,3,7.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
429,504749,1,3,8.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
430,504749,1,3,9.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
431,504749,1,3,10.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
432,504749,1,3,11.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
433,504749,1,3,12.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
434,504749,1,3,13.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
435,504749,1,3,14.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
436,504749,1,3,15.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
437,504749,1,3,16.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
438,504749,1,3,17.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
439,504749,1,3,18.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
440,504749,1,3,19.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
441,504749,1,3,20.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
442,504749,1,3,21.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
443,504749,1,3,22.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
444,504749,1,3,23.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
445,504749,1,3,24.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
446,504749,1,3,25.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
447,504749,1,3,26.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
448,504749,1,3,27.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
449,504749,1,3,28.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
450,504749,1,3,29.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
451,504749,1,3,30.0,26750098,5280489,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
452,504749,1,3,31.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
453,504749,1,3,32.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
454,504749,1,3,33.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
455,504749,1,3,34.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
456,504749,1,3,35.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
457,504749,1,3,36.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
458,504749,1,3,37.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
459,504749,1,3,38.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
460,504749,1,3,39.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
461,504749,1,3,40.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
462,504749,1,3,41.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
463,504749,1,3,42.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
464,504749,1,3,43.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
465,504749,1,3,44.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
466,504749,1,3,45.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
467,504749,1,3,46.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
468,504749,1,3,47.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
469,504749,1,3,48.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
470,504749,1,3,49.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
471,504749,1,3,50.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
472,504749,1,3,51.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
473,504749,1,3,52.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
474,504749,1,3,53.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
475,504749,1,3,54.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,55.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,56.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,57.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,58.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,59.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,60.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,61.0,26750098,5280489,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504832,1,1,,26750098,5280489,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
484,504834,1,1,,26750098,5280489,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
485,504847,1,1,,26750098,5280489,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
486,504865,1,1,,26750098,5280489,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
487,588211,2,3,,103401011,5280489,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
488,588212,2,3,,103401011,5280489,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
489,588213,2,3,,103401011,5280489,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
490,588220,2,3,,103401011,5280489,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
491,588511,1,2,,47193664,5280489,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
492,588579,1,1,,26750098,5280489,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
493,588627,1,1,,47193664,5280489,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
494,588675,1,1,,47193664,5280489,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
495,588676,1,1,,47193664,5280489,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
496,588834,2,1,,144205110,5280489,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
497,602332,1,1,,26750098,5280489,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
498,624030,1,2,,26750098,5280489,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
499,624031,1,2,,26750098,5280489,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
500,624032,1,2,,26750098,5280489,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
501,624044,1,2,,26750098,5280489,Inconclusive,8393992.0,24660.0,12.5797,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
502,624170,1,1,,26750098,5280489,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
503,624172,1,1,,26750098,5280489,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
504,624173,1,3,,26750098,5280489,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
505,624263,1,1,,26750098,5280489,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
506,624263,1,1,,26750098,5280489,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
507,624296,1,1,,26750098,5280489,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
508,624297,1,1,,26750098,5280489,Inactive,7705682.0,51053.0,2.6609,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
509,624349,1,2,,92307447,5280489,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
510,651631,4,1,,144205110,5280489,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
511,651632,4,1,,144205110,5280489,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
512,651633,4,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
513,651634,4,1,,144205110,5280489,Inactive,,,37.578,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
514,652048,1,2,,144205110,5280489,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
515,652051,1,1,,144205110,5280489,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
516,686978,1,1,,144205110,5280489,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
517,686979,1,1,,144205110,5280489,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
518,720516,2,1,,144205110,5280489,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
519,720532,1,1,,144205110,5280489,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
520,720533,1,1,,144205110,5280489,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
521,720552,2,1,,144205110,5280489,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
522,720579,2,1,,144205110,5280489,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
523,720580,1,1,,144205110,5280489,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
524,720634,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
525,720635,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
526,720637,2,1,,144205110,5280489,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
527,720641,1,2,,92307447,5280489,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
528,720674,2,2,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
529,720675,2,2,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
530,720678,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
531,720679,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
532,720680,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
533,720681,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
534,720682,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
535,720683,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
536,720684,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
537,720685,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
538,720686,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
539,720687,2,2,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
540,720691,4,1,,144205110,5280489,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
541,720692,3,1,,144205110,5280489,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
542,720693,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
543,720717,1,3,,92307447,5280489,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
544,720719,2,1,,144205110,5280489,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
545,720725,2,1,,144205110,5280489,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
546,743012,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
547,743014,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
548,743015,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
549,743033,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
550,743035,2,1,,144205110,5280489,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
551,743036,2,1,,144205110,5280489,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
552,743040,3,1,,144205110,5280489,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
553,743041,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
554,743042,3,1,,144205110,5280489,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
555,743053,2,1,,144205110,5280489,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
556,743054,2,1,,144205110,5280489,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
557,743063,2,1,,144205110,5280489,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
558,743064,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
559,743065,3,1,,144205110,5280489,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
560,743066,3,1,,144205110,5280489,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
561,743067,2,1,,144205110,5280489,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
562,743069,2,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
563,743074,2,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
564,743075,2,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
565,743077,2,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
566,743078,2,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
567,743079,3,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
568,743080,3,1,,144205110,5280489,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
569,743081,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
570,743083,3,1,,144205110,5280489,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
571,743084,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
572,743085,3,1,,144205110,5280489,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
573,743086,3,1,,144205110,5280489,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
574,743091,2,1,,144205110,5280489,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
575,743094,3,1,,144205110,5280489,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
576,743122,2,1,,144205110,5280489,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
577,743139,2,1,,144205110,5280489,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
578,743140,2,1,,144205110,5280489,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
579,743244,1,1,,144205110,5280489,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
580,977599,1,1,,103401011,5280489,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
581,977600,1,1,,103401011,5280489,Active,,,0.6166,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
582,977601,1,1,,103401011,5280489,Active,,,0.34,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
583,977602,1,2,,103401011,5280489,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
584,977603,1,2,,103401011,5280489,Active,,,2.9512099999999997,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
585,977604,1,2,,103401011,5280489,Active,,,2.26,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
586,1159524,1,1,,144205110,5280489,Active,,,5.0119,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
587,1159550,3,1,,252402481,5280489,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
588,1159580,2,1,,268734449,5280489,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
589,1159607,2,1,,312996207,5280489,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
590,1224863,1,1,,316920469,5280489,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
591,1259310,1,1,,321946545,5280489,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
592,1259310,1,1,,333472944,5280489,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
593,1259344,1,1,,144205110,5280489,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
594,1259355,1,1,,144205110,5280489,Inconclusive,,,31.6228,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
595,1259356,1,1,,144205110,5280489,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
596,1259389,1,1,,124633917,5280489,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
597,1259407,1,1,,363901195,5280489,Active,,,,,CCRIS mutagenicity studies,Other,,
598,1259408,1,1,,363896516,5280489,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
599,1259409,1,1,,363901195,5280489,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
600,1259410,1,1,,363901195,5280489,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
601,1259423,1,2,,354940673,5280489,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
